Latest news and updates from BIOTYPE
BIOTYPE achieves another IVDR milestone! We're thrilled to introduce Mentype® DIPscreen PCR Amplification Kit as a new INDEL-based tool for sensitive chimerism analysis after allogeneic hematopoietic stem cell transplantation (allo-HSCT) - now available in full compliance with IVDR (EU) 2017/746.
BIOTYPE is proud to reinforce its unwavering commitment to the highest quality and safety standards in molecular precision diagnostics. This achievement, through certification according to Regulation 2017/746 (IVDR), signifies our dedication to delivering cutting-edge solutions.
After an intensive, almost two-year process, BIOTYPE GmbH has received the certificate for our quality management system and for our first IVDR products according to (EU) 2017/746!
In molecular monitoring of hematopoietic chimerism, sensitivity is crucial to rapidly identify shifts in donor and recipient cell populations.
Determining NRAS status is crucial for guiding first-line therapy decisions in advanced colorectal cancer (CRC).
BIOTYPE GmbH, an internationally operating precision diagnostics company, announced today the launch of their latest additions to the MODAPLEX Molecular Profiling portfolio of highly multiplexed PCR-based assays
The first ever scientific publication of our MODAPLEX POLE/POLD1 Mutation Analysis Kit has been published! In early 2023 the publication was presented as a poster during that year’s ESMO congress and has now been accepted by a journal.
In the Saxon Network for Radionuclide Theranostics (SNRT), BIOTYPE joins forces with seven partners from science and industry to significantly shape progress in nuclear medicine through the evaluation of molecular biomarkers for patient stratification for therapy decisions and the development of new applications.
The "Gläserne Labor" (Transparent Laboratory) in Dresden is delighted to have received new equipment worth €16,800 as well as an additional cash donation of €2,500 for the purchase of further laboratory materials.
Today, we had the privilege of hosting the Prime Minister of the Free State of Saxony, Mr. Michael Kretschmer.
BIOTYPE presents a major upgrade of its MODAPLEX platform. The benchtop diagnostic platform for the fully integrated analysis of molecular biomarker signatures has been available since September 2023.
We are delighted to announce the launch of our newest product: QPCR POLE Mutation Analysis Kit!
BIOTYPE GmbH and STRATIFYER Molecular Pathology GmbH are pleased to announce their strategic collaboration aimed to develop innovative diagnostic tests to improve outcomes for patients with bladder cancer.
We presented a poster written in collaboration between the University Hospital Carl Gustav Carus, Dr Anke Weber, and Dr Matthias Preussler during this year's EHA2023 congress in Frankfurt.
We are excited to announce our new distribution partnership with Gencurix, Inc. for Germany. They are specialized in molecular cancer diagnostics and offer various ddPCR kits for detecting cancer mutations.
Our Tech Leads Dr. Christoph Schanzenbach and Dr. Matthias Preussler presented a poster titled "Syndromic testing for medium throughput in one workflow: flexible molecular analysis with the MODAPLEX platform" during the 10th Gene Quantification event #GQ2023 in Freising.
The first ever scientific publication of our MODAPLEX POLE/POLD1 Mutation Analysis Kit was presented during this year’s ESMO Gynaecological Cancers Congress in Barcelona!
We are thrilled about the designation of mdc medical device certification GmbH as the 9th EU-IVDR Notified Body.
We are pleased to announce that we have joined Scientist.com as a supplier to offer our contract development and manufacturing services! Scientist.com is the world's largest marketplace for medical research.
The Molecular Diagnostics Group GmbH (MDG) and the Swiss company 4D Lifetec AG announce a strategic partnership to further industrialize the 4D Lifetest™ liquid biopsy assay.
We are extremely proud that our biomarker assay development and manufacturing services have contributed to this success, and we look forward to continuing our cooperation with Cardior Pharmaceuticals.
At BIOTYPE, we believe that our customer’s success stories are also our own!
Transitioning into transformational leadership entails transformational changes. As Biotype is transforming and entering a new phase of development, it was vital for us to ensure that we decentralize decision making and adopt a more efficient approach. We value all aspects of our business that makes us a full-service provider in the molecular diagnostics industry, and we believe in a management that adopts a “Team Intelligence” approach.
We are delighted to announce that BIOTYPE is entering a new phase of its corporate development with the appointment of Dr. Norman Gerstner as new CEO and Dr. Felix Zörgiebel as new CTO succeeding Dr. Karim Tabiti effective April 1, 2022.
